CLX - The Clorox Company
NYSE
->
Consumer Defensive
->
Household & Personal Products
Oakland,
United States
Type: Equity
CLX price evolution
CLX
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $355 | $518 | $367 | $242 |
| Short term investments | ||||
| Net receivables | $679 | $581 | $688 | $678 |
| Inventory | $655 | $710 | $696 | $735 |
| Total current assets | $1804 | $1911 | $1828 | $1745 |
| Long term investments | ||||
| Property, plant & equipment | $1668 | $1645 | $1691 | $1674 |
| Goodwill & intangible assets | $1950 | $1949 | $1964 | $1972 |
| Total noncurrent assets | $4104 | $4080 | $4117 | $4073 |
| Total investments | ||||
| Total assets | $5908 | $5991 | $5945 | $5818 |
| Current liabilities | ||||
| Accounts payable | $1649 | $1678 | $1659 | $1722 |
| Deferred revenue | ||||
| Short long term debt | $339 | $435 | $137 | $226 |
| Total current liabilities | $2022 | $2228 | $1917 | $1996 |
| Long term debt | $2790 | $2768 | $2787 | $2799 |
| Total noncurrent liabilities | $3668 | $3632 | $3640 | $3650 |
| Total debt | $3129 | $3203 | $2924 | $3025 |
| Total liabilities | $5690 | $5860 | $5557 | $5646 |
| Shareholders' equity | ||||
| Retained earnings | $241 | $299 | $583 | $415 |
| Other shareholder equity | -$359 | -$494 | -$493 | -$498 |
| Total shareholder equity | $53 | -$37 | $220 | $3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $367 | $183 | $319 | $871 |
| Short term investments | ||||
| Net receivables | $688 | $681 | $604 | $648 |
| Inventory | $696 | $755 | $752 | $454 |
| Total current assets | $1828 | $1725 | $1829 | $2020 |
| Long term investments | $63 | |||
| Property, plant & equipment | $1691 | $1676 | $1634 | $1394 |
| Goodwill & intangible assets | $1964 | $2442 | $2493 | $2471 |
| Total noncurrent assets | $4117 | $4433 | $4505 | $4193 |
| Total investments | ||||
| Total assets | $5945 | $6158 | $6334 | $6213 |
| Current liabilities | ||||
| Accounts payable | $1659 | $1469 | $1675 | $1329 |
| Deferred revenue | ||||
| Short long term debt | $137 | $315 | $381 | $64 |
| Total current liabilities | $1917 | $1784 | $2056 | $1418 |
| Long term debt | $2787 | $2788 | $2785 | $3058 |
| Total noncurrent liabilities | $3640 | $3645 | $3686 | $3887 |
| Total debt | $2924 | $3103 | $3166 | $3122 |
| Total liabilities | $5557 | $5429 | $5742 | $5305 |
| Shareholders' equity | ||||
| Retained earnings | $583 | $1048 | $1036 | $3567 |
| Other shareholder equity | -$493 | -$479 | -$546 | -$640 |
| Total shareholder equity | $220 | $556 | $411 | $908 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1990 | $2019 | $1915 | |
| Cost of revenue | $1124 | $1157 | $1115 | |
| Gross Profit | $866 | $862 | $800 | |
| Operating activities | ||||
| Research & development | $32 | $38 | $35 | |
| Selling, general & administrative | $508 | $540 | $517 | |
| Total operating expenses | $704 | $604 | $1021 | |
| Operating income | $162 | $258 | -$221 | |
| Income from continuing operations | ||||
| EBIT | $159 | $253 | -$223 | |
| Income tax expense | $40 | $56 | -$36 | |
| Interest expense | $26 | $21 | $24 | |
| Net income | ||||
| Net income | $93 | $176 | -$211 | |
| Income (for common shares) | $93 | $176 | -$211 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7389 | $7107 | $7341 | $6721 |
| Cost of revenue | $4481 | $4562 | $4142 | $3658 |
| Gross Profit | $2908 | $2545 | $3199 | $3063 |
| Operating activities | ||||
| Research & development | $138 | $132 | $149 | $145 |
| Selling, general & administrative | $1917 | $1663 | $1794 | $1644 |
| Total operating expenses | $2580 | $1832 | $2200 | $1779 |
| Operating income | $328 | $713 | $999 | $1284 |
| Income from continuing operations | ||||
| EBIT | $316 | $704 | $990 | $1284 |
| Income tax expense | $77 | $136 | $181 | $246 |
| Interest expense | $90 | $106 | $99 | $99 |
| Net income | ||||
| Net income | $149 | $462 | $710 | $939 |
| Income (for common shares) | $149 | $462 | $710 | $939 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $93 | $22 | $176 | -$211 |
| Operating activities | ||||
| Depreciation | $57 | $61 | $62 | $60 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16 | $13 | $13 | $29 |
| Total cash flows from operations | $153 | $20 | $430 | $341 |
| Investing activities | ||||
| Capital expenditures | -$52 | -$24 | -$84 | -$56 |
| Investments | ||||
| Total cash flows from investing | -$33 | -$23 | -$81 | -$55 |
| Financing activities | ||||
| Dividends paid | -$149 | -$149 | -$146 | -$146 |
| Sale and purchase of stock | -$7 | $6 | $23 | $6 |
| Net borrowings | -$103 | $298 | -$89 | -$71 |
| Total cash flows from financing | -$259 | $155 | -$227 | -$211 |
| Effect of exchange rate | -$23 | $1 | ||
| Change in cash and equivalents | -$162 | $152 | $122 | $76 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $149 | $462 | $710 | $939 |
| Operating activities | ||||
| Depreciation | $236 | $224 | $211 | $180 |
| Business acquisitions & disposals | -$85 | |||
| Stock-based compensation | $73 | $52 | $50 | $50 |
| Total cash flows from operations | $1158 | $786 | $1276 | $1546 |
| Investing activities | ||||
| Capital expenditures | -$228 | -$251 | -$331 | -$254 |
| Investments | ||||
| Total cash flows from investing | -$223 | -$229 | -$452 | -$252 |
| Financing activities | ||||
| Dividends paid | -$583 | -$571 | -$558 | -$533 |
| Sale and purchase of stock | $33 | -$20 | -$802 | -$86 |
| Net borrowings | -$188 | -$83 | $96 | |
| Total cash flows from financing | -$753 | -$689 | -$1391 | -$523 |
| Effect of exchange rate | -$6 | $12 | -$5 | |
| Change in cash and equivalents | $182 | -$138 | -$555 | $766 |
News
|
Clorox (NYSE:CLX) PT Lowered to $150.00
ETF DAILY NEWS
3 May 2024
|
|
MONECO Advisors LLC Purchases Shares of 1,655 The Clorox Company (NYSE:CLX)
ETF DAILY NEWS
3 May 2024
|
|
Why Clorox Stock Dropped on Wednesday
Motley Fool via Yahoo Finance
2 May 2024
|
|
Wells Fargo cuts Clorox stock price target, retains underweight rating By Investing.com
Investing.com
2 May 2024
|
|
Why Clorox (CLX) is a Top Growth Stock for the Long-Term
Zacks via Yahoo Finance
2 May 2024
|
|
Clorox (CLX) Q3 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance
1 May 2024
|
|
The Clorox Company (NYSE:CLX) Receives Average Recommendation of “Reduce” from Analysts
ETF DAILY NEWS
1 May 2024
|
|
The Clorox Company (NYSE:CLX) Q3 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
1 May 2024
|
|
Clorox (NYSE:CLX) Misses Q1 Revenue Estimates By Stock Story
Investing.com
30 Apr 2024
|
|
Here's How Clorox (CLX) is Placed Ahead of Q3 Earnings Release
Zacks via Yahoo Finance
29 Apr 2024
|
Fundamentals
| Market cap | $17.28B |
|---|---|
| Enterprise value | $20.06B |
| Shares outstanding | 124.08M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 16.03% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 41.95 |
| Book/Share | 3.32 |
| Cash/Share | 2.86 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 25.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | 0.57 |